END TREATMENT RESPONSE OF SOFOSBUVIR (SOVALDI) PLUS RIBAVIRIN IN HEPATITIS C PATIENT GENOTYPE 3 AT GASTROENTEROLOGY AND HEPATALOGY UNIT LADY READING HOSPITAL PESHAWAR
Objective: To determine the end Treatment Response (ETR) rate in HCV genotype 3 treated with Sofosbuvir and Ribavirin.
Material and Method: This study was done at HEPATITIS CLINIC PGMI LADY READING HOSPITAL PESHAWARfrom
September 2014 to JUNE 2016. Prior approvalfor this research was taken from ethical committee of lady READING
A total of 335 patients were selected after properly applying inclusion and exclusion criteria.All patients received Sofosbuvir
(SOVALDI) 400 mg and weight based ribavirin for a period of six months.All patients were fallowed with Full
Blood Count and LFT’s monthly and PCR at week 4,12 and 24.
Results: In this study total of 335 patients were enrolled.There were 184 male and 151 female. 96.4% of males and
96.68 % of the females achieved ETR. Of total, 187 patients were treatment naïve and 180 patients (96.84%) achieved
ETR. The remaining 148 were treatment experienced and 140(92.6%)achieved ETR.
Conclusion: The combination of sofosbuvir and Ribavirin has high ETR rates in both genderas well as in treatment